Cabergoline Use and Pregnancy Outcomes: A Systematic Review
Rattachement africain : ca. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
INTRODUCTION: Lack of available expert guidelines leads clinicians to interrupt cabergoline treatment upon confirmation of pregnancy and consider switching to bromocriptine, which is more commonly used during pregnancy but is poorly tolerated. OBJECTIVE: The objective of this review was to evaluate pregnancy outcomes, primarily major malformations and spontaneous abortions, after pregnancy exposure to cabergoline during the first trimester compared to pregnancy exposure to other comparators or no treatment. METHODS: An Embase, Pubmed, Google Scholar, and ClinicalTrials.gov search was performed. Full articles published before October 27, 2022, and evaluating the effect of cabergoline on major malformations and spontaneous abortions were considered for inclusion in the review. Search results were manually screened and selected by two independent reviewers. RESULTS: Totally, 2186 records were identified. After removal of duplicates and screening of abstracts, 65 full-text articles were consulted. Thirty articles corresponded to our selection criteria and were included in the systematic review. This review identified 1662 pregnancies exposed to cabergoline. Most studies did not find an increased risk of congenital malformations or spontaneous abortions with cabergoline compared to other comparators or no treatment. Overall study quality was low, and there was high heterogeneity between studies. CONCLUSION: This review revealed no negative impact on major malformations and spontaneous abortions of cabergoline use in pregnancy compared to other comparators or no treatment. However, additional high-quality studies are needed to further study the safety of cabergoline use during pregnancy. TRIAL REGISTRATION: PROSPERO, CRD42021256219 (October 19, 2021).
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Cabergoline Use and Pregnancy Outcomes: A Systematic Review
- Date Crossref
- 01/03/2025
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Centre Hospitalier Universitaire Sainte-Justine pays non établi dans la noticeÉtablissement de santé
-
Université de Montréal Division of Reproductive Endocrinology and Infertility pays non établi dans la noticeUniversité ou école supérieure
-
Jewish General Hospital Lady Davis Institute for Medical Research pays non établi dans la noticeÉtablissement de santé
-
McGill University pays non établi dans la noticeUniversité ou école supérieure
-
Department of Pharmacy CHU Sainte‐Justine Montreal Quebec Canada pays non établi dans la noticeÉtablissement de santé
-
Department of Obstetrics and Gynecology CHU Sainte‐Justine Montreal Quebec Canada Assisted Reproduction Technology Center pays non établi dans la noticeÉtablissement de santé
Centre Hospitalier Universitaire Sainte-Justine, Division of Reproductive Endocrinology and Infertility — Université de Montréal et Lady Davis Institute for Medical Research — Jewish General Hospital, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.